10-K: IQVIA Reports Solid 2025 Results, Strategic AI Focus

IQVIA Holdings Inc. reports solid financial results for 2025, driven by growth in Technology & Analytics Solutions and strategic investments in AI, despite industry uncertainties.

Summary

• Total revenues increased 5.9% to $16,310 million in 2025, up from $15,405 million in 2024.
• Constant currency revenue growth was approximately 4.8% ($737 million) in 2025.
• Technology & Analytics Solutions revenue grew 7.6% to $6,626 million in 2025.
• Research & Development Solutions revenue increased 4.3% to $8,896 million in 2025, with improved growth rates in the second half of the year.
• Contract Sales & Medical Solutions revenue rose 9.7% to $788 million in 2025.
• Net income for 2025 was $1,361 million, a slight decrease from $1,373 million in 2024.
• Diluted earnings per share (EPS) increased to $7.84 in 2025 from $7.49 in 2024.
• Cash flows from operating activities totaled $2,654 million in 2025.
• The company invested $1,714 million, net of cash, in business acquisitions during 2025.
• Total remaining performance obligations were approximately $34.2 billion as of December 31, 2025, with about 30% expected to convert to revenues in the next 12 months.
• The Board authorized an additional $2,000 million for stock repurchases on February 5, 2025, increasing the total authorization under the Repurchase Program to $13,725 million.
• In 2025, 7.4 million shares of common stock were repurchased for $1,244 million under the Repurchase Program.
• Total indebtedness stood at $15,800 million as of December 31, 2025.
• Effective January 1, 2026, the company will restructure its reportable segments from three to two: Commercial Solutions (combining Technology & Analytics Solutions and Contract Sales & Medical Solutions) and Research & Development Solutions (incorporating Real-World Late Phase and certain other Real-World offerings).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting solid revenue growth and strategic investments in AI and acquisitions, which position the company for future expansion. However, the slight dip in net income and increased restructuring costs warrant careful monitoring.

Positives

• Overall revenue growth of 5.9% in 2025, demonstrating continued expansion.
• Strong performance in the Technology & Analytics Solutions segment, with a 7.6% revenue increase.
• Improved growth rates in the Research & Development Solutions segment during the second half of 2025, indicating recovery from earlier client cautiousness.
• Generated substantial cash flow from operating activities of $2,654 million in 2025.
• Significant remaining performance obligations of $34.2 billion provide strong future revenue visibility.
• Increased stock repurchase authorization by an additional $2,000 million, signaling confidence in financial health and commitment to shareholder returns.
• Diluted EPS increased to $7.84 in 2025, reflecting improved per-share profitability.
• Maintained effective internal control over financial reporting as of December 31, 2025.
• Commitment to responsible AI development and 'Healthcare-grade AI' positions the company for future innovation.
• High employee engagement, with 91% of employees feeling they are acquiring necessary skills and 85% seeing a clear link to the company's vision.
• Favorable impact on the effective income tax rate in 2025 due to changes in the geographic mix of earnings.

Negatives

• Net income slightly decreased from $1,373 million in 2024 to $1,361 million in 2025.
• The Research & Development Solutions segment was impacted by client cautiousness, although growth improved in the latter half of the year.
• Cost of revenues, exclusive of depreciation and amortization, increased by 8.5% in 2025, outpacing overall revenue growth.
• Interest income decreased in 2025 compared to 2024, primarily due to lower deposit rates.
• Interest expense increased in 2025 due to higher outstanding debt balances.
• Restructuring costs increased to $105 million in 2025 from $67 million in 2024.
• Revenue growth in Research & Development Solutions was impacted by a decrease in COVID-19 related work.
• The company faces risks from potential increased competition from lower-cost generic products, which may reduce client R&D spending.

Risks

• Potential loss or delay of large contracts or multiple contracts, as most Research & Development Solutions contracts are terminable on short notice (30-90 days).
• Financial results may be adversely affected by underpricing contracts, cost overruns, or delays in documenting change orders.
• Failure to meet productivity objectives under internal business transformation initiatives could impact competitiveness and operating results.
• Inability to successfully identify, acquire, and integrate existing businesses, services, and technologies.
• Inability to attract suitable investigators and patients for clinical trials.
• Loss of key personnel or inability to recruit additional qualified personnel, or requirement to substantially increase wage rates.
• Dependence on third parties for data and support services; suppliers might restrict use or refuse to license data.
• Security breaches and unauthorized use of IT systems and information, including those of vendors, could expose the company to loss.
• Challenges with the acquisition, development, enhancement, or deployment of technology, especially AI-enabled offerings, which may not perform as intended or be adopted by customers.
• Data protection, privacy, and similar laws and regulations (e.g., HIPAA, GDPR, PIPL) restrict access, use, and disclosure of personal information, and failure to comply could harm the business.
• Consolidation in client industries may reduce the volume of services purchased by consolidated clients.
• Adverse effects from client or therapeutic concentration.
• Relationships with existing or potential clients who are in competition with each other may adversely impact the degree to which other clients or potential clients use services.
• Risk of initiating a clinical trial for a client who then becomes unwilling or unable to fund completion, potentially requiring the company to complete or wind down at its own expense.
• Disruptions in credit and capital markets and unfavorable general economic conditions could negatively affect the business.
• Fluctuations in the effective income tax rate for a variety of reasons.
• Exposure to international economic, political, and other risks, including compliance with local laws, trade barriers, inflation, and geopolitical events.
• Environmental events may have an impact on the business, including extreme weather events on critical infrastructure.
• Evolving and diverging expectations and requirements on sustainability-related matters from a wide range of stakeholders.
• Exchange rate fluctuations may affect results of operations and financial condition.
• Exposure to liabilities under anti-corruption laws, including the United States Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act.
• Risks related to sales to government entities, including terminable contracts and public-sector budgetary cycles.
• Research & Development Solutions business could subject the company to potential liability for personal injury or death of patients.
• Contract Sales & Medical Solutions business could result in liability if a drug causes harm to a patient.
• Insurance may not cover all indemnification obligations and other liabilities associated with operations.
• The biopharmaceutical services industry is highly competitive, and failure to compete effectively or rapidly adapt to technological change could materially impact the business.
• Outsourcing trends in the biopharmaceutical industry and changes in aggregate spending and research and development budgets could adversely affect operating results and growth rate.
• The business may be materially and adversely impacted by factors affecting the biopharmaceutical and healthcare industries, such as financial pressures on clients.
• Healthcare reform and potential additional reforms (e.g., Inflation Reduction Act of 2022) may adversely impact the biopharmaceutical industry and reduce demand for services.
• Actions by government regulators or clients to limit a prescription's scope or withdraw an approved drug from the market could adversely affect the business.
• Laws restricting biopharmaceutical sales and marketing practices may adversely impact demand for services.
• Research & Development Solutions clients face intense competition from lower-cost generic products, which may lower their spending on services.
• Restrictions imposed in senior secured credit facilities and other outstanding indebtedness may limit the ability to operate the business and finance future operations.
• Interest rate fluctuations and the ability to deduct interest expense may affect results of operations and financial condition.
• Provisions of corporate governance documents could make an acquisition of IQVIA difficult and may prevent attempts by stockholders to replace or remove management.
• Operating results and share price may be volatile, which could cause the value of stockholders' investments to decline.
• No current plans to pay regular cash dividends on common stock.
• The certificate of incorporation contains a provision renouncing any interest and expectancy in certain corporate opportunities identified by TPG Global, Bain Capital, CPP Investment Board Private Holdings Inc., and Leonard Green & Partners, L.P., and their affiliates.

Future Outlook

The company anticipates continued growth in healthcare spending in emerging markets and expects approximately 375 new molecular entities (NMEs) to be approved between 2026 and 2030, averaging 75 per year. This is expected to drive sustained demand for biopharmaceutical services, particularly for companies with global reach and broad offerings. The company plans to continue investing in and exploring strategic acquisitions to expand its platform and service capabilities. Restructuring actions are expected to continue throughout 2026 to streamline global operations. A goodwill impairment test will be performed in 2026 due to the upcoming segment restructuring. The company will adopt a new segment reporting structure (Commercial Solutions and Research & Development Solutions) effective January 1, 2026, with recast information to be reflected in the Q1 2026 Form 10-Q. The company will also continue to monitor and evaluate OECD Pillar Two administrative guidance and expects to contribute approximately $34 million to its defined benefit plans in 2026.

Management Comments

• We delivered solid results in 2025, navigating a year of industry uncertainty resulting from a variety of macroeconomic factors that together slowed customer decision-making.
• Our Technology & Analytics Solutions business continued its growth trajectory, with revenue increasing 7.6% over 2024.
• While our Research & Development Solutions segment has been impacted by client cautiousness, we grew full-year revenue 4.3% over 2024, driven by improved growth rates in the second half of the year.
• We achieved $2,654 million of cash flows from operating activities, and invested $1,714 million, net of cash, to acquire businesses that will strengthen and expand our offerings moving forward, including acquisitions in all three reportable segments.
• We ended the year with total company remaining performance obligations of approximately $34.2 billion as of December 31, 2025.
• We are committed to using artificial intelligence ('AI') responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry.
• We believe that our global clinical development capabilities, including our expertise in biomarkers and genomics and our global laboratory network, position us well to help biopharmaceutical companies manage the complexities inherent in an environment where this type of expertise is important.
• We believe we are well positioned to take advantage of these global trends in healthcare.
• Our approximately 93,000 employees drive our vision to power smarter healthcare for everyone, everywhere.

Industry Context

StockSavvy.ai notes that IQVIA operates in a highly competitive biopharmaceutical services industry, facing competition from traditional Clinical Research Organizations (CROs), in-house client departments, universities, and large technology companies. The industry is characterized by increasing R&D complexity, financial pressures driving efficiency needs, and the evolving integration of vast data sources, all of which IQVIA aims to address with its Connected Intelligence and AI-powered solutions. The growth of emerging markets and the expected approval of 375 new molecular entities (NMEs) between 2026 and 2030 highlight a robust, albeit complex, market opportunity. The company's strategic focus on AI and data analytics aligns with broader industry trends towards digital transformation and value-based healthcare.

Comparison to Industry Standards

• IQVIA's R&D Solutions backlog of $32.7 billion as of December 31, 2025, with approximately 30% expected to convert to revenue in the next 12 months, provides a strong indicator of future revenue, comparable to other large global CROs like ICON plc and Parexel International Corporation, which also rely on substantial backlogs for revenue visibility.
• The company's market opportunity of approximately $335 billion in 2025 for outsourced R&D, real-world evidence, and technology-enabled operations positions it as a significant player in a market also served by competitors such as Accenture, Deloitte, and Pharmaceutical Product Development, Inc. (part of Thermo Fisher Scientific Inc.).
• IQVIA's claim of delivering information and insights on approximately 90% of the world's pharmaceuticals (as measured by 2024 sales) suggests a dominant market position in healthcare intelligence, a metric that few, if any, competitors like Relx or S&P Global Inc. can match in breadth.
• The company's investment in Healthcare-grade AI and its Center for Defensible Data and AI indicates a proactive approach to technological advancement, aiming to differentiate itself from competitors like Medidata (Part of Dassault Systèmes) and Veeva, who also offer technology solutions in the life sciences space.

Management Changes

Corporate Governance

Legal Proceedings

• The company and its subsidiaries are involved in legal and tax proceedings, claims, and litigation arising in the ordinary course of business.
• Management does not expect the impact of pending matters, either individually or in the aggregate, to have a material adverse effect on the company's results of operations, cash flows, or financial position.
• One or more unfavorable outcomes in any claim or litigation against the company could have a material adverse effect for the period in which it is resolved.

Related Party Transactions

• The company has entered into transactions with related parties that are not deemed to be material.

Stakeholder Impact

• Shareholders: Potential for increased value through stock repurchases and long-term growth strategy, but also risks from market volatility and anti-takeover provisions.
• Employees: Continued investment in human capital (recruitment, development, retention), health & well-being programs, and financial rewards. Restructuring actions may lead to job eliminations.
• Customers (Biopharmaceutical, Healthcare): Enhanced service offerings through AI and Connected Intelligence, broader market penetration, and strategic acquisitions aim to improve client outcomes and efficiency. Risks include client cautiousness and consolidation.
• Data Suppliers: Continued reliance on third-party data suppliers, with risks if suppliers restrict use or refuse to license data.
• Creditors: Debt refinancing and management of substantial indebtedness, with covenants limiting certain corporate actions.

Next Steps

• Continue to innovate through IQVIA Connected Intelligence, leveraging information, advanced analytics, transformative technology, and domain expertise.
• Build upon extensive client relationships and global presence.
• Expand the penetration of offerings to the broader healthcare marketplace, including payers, providers, healthcare professionals, governments, and non-governmental organizations.
• Expand the portfolio through strategic acquisitions to strengthen value proposition to clients.
• Continue restructuring actions throughout 2026 to streamline global operations and reduce overcapacity.
• Perform a goodwill impairment test in 2026 due to the segment restructuring.
• Implement new segment reporting structure (Commercial Solutions and Research & Development Solutions) effective January 1, 2026, with recast information to be reflected in the Q1 2026 Form 10-Q.
• Monitor and evaluate OECD Pillar Two administrative guidance in the context of jurisdictions that adopt it.
• Expect to contribute approximately $34 million in required contributions to pension and postretirement benefit plans during 2026.

Key Dates

Recommendation

IQVIA demonstrates solid revenue growth and strategic initiatives in AI and acquisitions, which are positive long-term drivers. However, the slight decline in net income, increased operating costs, and ongoing restructuring indicate some near-term challenges and integration risks. The company's strong backlog and liquidity provide stability, but the competitive landscape and macroeconomic uncertainties suggest a 'Hold' recommendation, advising investors to monitor the execution of strategic shifts and the impact of restructuring on profitability and growth.

Keywords

Healthcare, Life Sciences, Clinical Research, AI, Data Analytics, Pharmaceutical, Biotechnology, CRO, Real-World Evidence, Technology Solutions, Contract Sales, Medical Solutions, SEC Filing, 10-K, Financial Report, Corporate Governance, Risk Management, Stock Repurchase, Debt, Mergers & Acquisitions